Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.69 |
| ▸ | BCR | P11274 | 14/20 | 0.69 |
| ▸ | EGFR | P00533 | 5/20 | 0.68 |
| ▸ | SRC | P12931 | 4/20 | 0.68 |
| ▸ | PRKACA | P17612 | 1/20 | 0.68 |
| ▸ | PRKACG | P22612 | 1/20 | 0.68 |
| ▸ | PRKACB | P22694 | 1/20 | 0.68 |
| ▸ | PRKCA | P17252 | 8/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | ITK | Q08881 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | PRKCG | P05129 | 1/20 | 0.58 |
| ▸ | PRKCB | P05771 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | PRKCH | P24723 | 1/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2081770 | 0.99 | ABL1 (0.68) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL30175794 | 0.89 | ABL1 (0.73) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL3857801 | 0.85 | ABL1 (0.68) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL7471161 | 0.85 | ABL1 (0.68) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL31671091 | 0.85 | ABL1 (0.51) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL17782807 | 0.83 | ABL1 (0.77) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL29555505 | 0.82 | ABL1 (1.00) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL2392 | 0.82 | ABL1 (1.00) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL29366999 | 0.82 | ABL1 (1.00) | ABL1BCREGFRSRCPRKACA | |
| SCHEMBL3868291 | 0.82 | ABL1 (0.76) | ABL1BCREGFRSRCPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | claimed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | claimed |
| WO-2011070588-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2011-06-16 | — | — | WO | claimed |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2385035-B1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | HARBIN GLORIA PHARMACEUTICALS CO LTD (CN) | 2014-06-25 | — | — | EP | disclosed |
| US-8703771-B2 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor | HARBIN GLORIA PHARMACEUTICALS CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | disclosed |
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | disclosed |
| US-20110319420-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | HARBIN GLORIA PHARMACEUTICALS CO., LTD (CN) | 2011-12-29 | — | — | US | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| EP-1783126-A2 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1684951-A | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2005-10-19 | — | — | CN | disclosed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| US-20040248918-A1 | Anticancer agents | IL YANG PHARM. CO., LTD. | 2004-12-09 | — | — | US | disclosed |
| WO-2004099186-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO., LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099187-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM. CO. LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ABL1, JAK2, ABL2 | ABL1 1/4885BCR 9/4885EGFR 322/4885 |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | ABL1 197/4885BCR 1066/4885EGFR 2057/4885 |
| US-20110319420-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | KIT, ABL1, ABL2 | ABL1 2/4885BCR 7/4885EGFR 446/4885 |
| US-20040248918-A1 | Anticancer agents | BRDT, CHIA, RNASE1 | ABL1 1106/4885BCR 2730/4885EGFR 1597/4885 |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | MKI67, CDK4, NME2 | ABL1 19/4885BCR 1069/4885EGFR 983/4885 |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | ABL1 104/4885BCR 4526/4885EGFR 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.